Tromsø, Norway, May 13[th], 2024 - ArcticZymes Technologies (OSE: AZT) announces
Nominations for new Board members and the resignation of the Chairman and a
Board member.

ArcticZymes today announces changes to its governance structure. The Election
committee has proposed changes to the Board to guide and strengthen the
strategic and commercial development of the company.

Nomination of New Board Members

ArcticZymes is pleased to introduce three distinguished individuals nominated to
join its Board of directors. These nominees bring expertise and experience in
the biomanufacturing and financial sectors, enriching ArcticZymes' strategic
direction, commercialization efforts, and governance practices:

  · Mrs. Sharon Brownlow: With a background in Biotech and extensive experience
in the cell and gene therapy industry, Mrs. Brownlow is renowned for blending
her scientific roots with entrepreneurial drive. Her proven track record
includes senior commercial roles in Catapult and Cobra Biologics, where she
effectively drove strategic business momentum and long-term revenue growth.

  · Mr. Petter Dragesund: Former Senior Partner at Pareto Securities, Mr.
Dragesund boasts nearly three decades of experience in investment banking.
Serving in various capacities at Pareto from 1992 to 2021, including Head of the
Corporate Finance department from 2001 to 2014, he brings invaluable financial
acumen to the Board. Since 2021, Mr. Dragesund has been an independent investor,
further broadening his insights into market dynamics.

  · A third Board member, currently a Life Science Executive, will be nominated
shortly. With a remarkable track record in scaling public life science companies
and devising successful growth strategies, this individual possesses deep
insights into the challenges and opportunities within drug development and
commercialization broadly.

Resignation of Chairman and Board Member

Mrs. Marie Roskrow, Chairman of the Board, has resigned, effective immediately.
During her six-year tenure, Mrs. Roskrow played a pivotal role in elevating
ArcticZymes into a globally profitable player in the life science tools sector.
Her leadership laid a robust foundation for long-term growth, for which the
Election committee extends its sincere appreciation.

Board member Mrs. Jane Theaker has also resigned, citing personal reasons. The
committee acknowledges Mrs. Theaker's valuable contributions and thanks her for
her service.

New date of the Annual General Meeting (AGM) is June 26[th], 2024

For practical reasons ArcticZymes has decided to move its Annual General Meeting
(AGM), originally scheduled for June 5[th], to June 26[th], 2024. The financial
calendar will be updated as well.

-Ends-

For more information, please contact:

ArcticZymes Technologies ASA
CEO,  MIchael B. Akoh                        Tel: +46 (0) 70 262 37 15
CFO, Børge Sørvoll                              Tel: +47 952 90 187
ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.

Listed on the Oslo Stock Exchange since 2005 originally under the [AZT] ticker.
Its headquarters are based in Tromsø, Norway, at the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large
portfolio of patents.

For more information, please visit the website: www.arcticzymes.com